Drug intelligence / Profile preview

ZY-A001

Development stage: Unknown
Lead developer: Yabao Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

ZY-A001 is an investigational small molecule antiviral agent developed by Yabao Pharmaceutical Group for the treatment of acute upper respiratory tract infections (AURTI). It is classified as a Class 1 innovative chemical drug in China and specifically targets the human parainfluenza virus (HPIV), a common pathogen responsible for respiratory distress in pediatric and immunocompromised populations. ZY-A001 is designed to inhibit viral activity, potentially by interfering with viral entry or replication processes, thereby reducing the severity and duration of respiratory symptoms. The drug has progressed into Phase 1 clinical trials in China to evaluate its safety, tolerability, and pharmacokinetic profile in healthy volunteers and patients.

Beyond the preview

Go deeper on ZY-A001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZY-A001.

Explore the full profile